4 completed. 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 3 | 1 | Completed 1 |
Follow leniolisib: new trials by email Literature Review of leniolisib trials Research Report on leniolisib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Leniolisib for Immune Dysregulation in CVID Leniolisib - Common Variable Immunodeficiency (CVID) | Phase 2 | Completed | Pharming Technologies B.V. | 27 | 2025-02-12 | 2026-09-18 |
| Leniolisib for Immune Dysregulation in PIDs Leniolisib - Primary Immunodeficiency Disorders (PIDs) | Phase 2 | Completed | Pharming Technologies B.V. | 13 | 2024-10-21 | 2026-10-19 |
| Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome CDZ173, Placebo - Primary Sjögren's Syndrome | Phase 2 | Completed | Novartis Pharmaceuticals | 30 | 2016-06-01 | 2021-01-05 |
| Study of Efficacy of CDZ173 in Patients With APDS/PASLI CDZ173, Placebo - Common Variable Immunodeficiency (CVID), APDS / PASLI | Phase 2 / Phase 3 | Completed | Novartis Pharmaceuticals | 37 | 2015-08-24 | 2022-08-10 |
Common Variable Immunodeficiency (2) · Activated PI3K-delta Syndrome (1) · Primary Immunodeficiency Diseases (1)
Novartis Pharmaceuticals (2) · Pharming Technologies B.V. (2)
United States (3) · Germany (2) · United Kingdom (2) · Belarus (1) · Czechia (1) · Hungary (1) · Ireland (1) · Italy (1) · Netherlands (1) · Russia (1) · Spain (1)
Gulbu Uzel, M.D. (1) · Koneti V Rao, MD (1) · Virgil Dalm, MD (1)
PMID 28972011, PMID 36399712, PMID 41091701, PMID 41608120
2014 (2)